Form 4: MeiraGTx Holdings Chief Medical Officer Reports Share Transactions Following Vesting of Restricted Share Units

MeiraGTx Holdings' Chief Medical Officer, Robert K. Zeldin, reported the vesting of restricted share units and subsequent share transactions on January 14, 2025.

Summary

• Robert K. Zeldin, Chief Medical Officer of MeiraGTx Holdings, reported transactions related to the vesting of restricted share units.
• On January 14, 2025, 37,500 restricted share units vested, converting into 37,500 ordinary shares.
• Following the vesting, 15,149 shares were withheld to cover tax obligations at a price of $5.77 per share.
• After these transactions, Zeldin directly owns 127,423 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation, which is generally neutral to positive. The vesting of shares is a positive sign of alignment with company performance.

Positives

• The vesting of restricted share units indicates a continued alignment of the Chief Medical Officer's interests with the company's performance.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies.

Comparison to Industry Standards

• The vesting of restricted share units is a standard practice in executive compensation across the biotechnology industry.
• Similar transactions are regularly reported by executives at comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to executive compensation.

Key Dates

Keywords

MeiraGTx Holdings, MGTX, Robert K. Zeldin, Chief Medical Officer, restricted share units, share vesting, insider trading, SEC Form 4